Recurrent pleomorphic adenoma: is treatment considerably delayed thus affecting surgical morbidity?

Recurrent pleomorphic adenoma: is treatment considerably delayed thus affecting surgical morbidity?

Acta Otolaryngol. 2017 Nov 16;:1-4

Authors: Glikson E, Sagiv D, Mansour J, Bedrin L, Talmi YP, Alon EE

Abstract
OBJECTIVE: To examine the incidence of late presentation of patients with recurrent pleomorphic adenoma (RPA) of the parotid gland.
METHODS: This is a retrospective analysis of patients treated in our center. We examined patients demographics, disease characteristics, treatment, and outcome and as well as the time period length from the first discovery of a recurrent mass until seeking treatment at our clinic and its effect on morbidity.
RESULTS: A total of 30 patients were included. 26% underwent initial enucleation in other institutions. In eight patients (26%), the recurrence of the mass was second or higher. The patients average time period length until seeking treatment was 2.48 years, with 33% of patients showing a time period length of over three years. Multifocal tumor, tumor diameter larger than 2 cm and facial nerve involvement were found in 15 (50%),16 (53.3%) and seven (25%) patients respectively. Patient's delay of presentation by ≥3 years was associated with a tumor size of ≥2 cm (Relative Risk [RR] = 2, p = .02). Patient's delay of presentation by ≥2 years was also associated with a trend towards a higher rate of post-operative facial nerve palsy (RR = 3.37, p = .07, CI = 0.88-12.85).
CONCLUSION: Most patients with RPA were presented late, thus affecting disease extent and surgical morbidity.

PMID: 29141486 [PubMed - as supplied by publisher]

from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/2ATGpt7